These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 29426605)

  • 21. Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level.
    Sakaizawa K; Goto Y; Kiniwa Y; Uchiyama A; Harada K; Shimada S; Saida T; Ferrone S; Takata M; Uhara H; Okuyama R
    Br J Cancer; 2012 Feb; 106(5):939-46. PubMed ID: 22281663
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New observations in tumor cell plasticity: mutational profiling in a case of metastatic melanoma with biphasic sarcomatoid transdifferentiation.
    Rupp NJ; Rechsteiner M; Freiberger SN; Lenggenhager D; Urosevic M; Burger IA; Rushing EJ; Mihic-Probst D
    Virchows Arch; 2018 Oct; 473(4):517-521. PubMed ID: 29785541
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular and genetic diversity in the metastatic process of melanoma.
    Harbst K; Lauss M; Cirenajwis H; Winter C; Howlin J; Törngren T; Kvist A; Nodin B; Olsson E; Häkkinen J; Jirström K; Staaf J; Lundgren L; Olsson H; Ingvar C; Gruvberger-Saal SK; Saal LH; Jönsson G
    J Pathol; 2014 May; 233(1):39-50. PubMed ID: 24399611
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of BRAF-V600E and V600K in melanoma circulating tumour cells by droplet digital PCR.
    Reid AL; Freeman JB; Millward M; Ziman M; Gray ES
    Clin Biochem; 2015 Oct; 48(15):999-1002. PubMed ID: 25523300
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BRAF-V600 Mutation Heterogeneity in Primary and Metastatic Melanoma: A Study With Pyrosequencing and Immunohistochemistry.
    Yaman B; Kandiloğlu G; Akalin T
    Am J Dermatopathol; 2016 Feb; 38(2):113-20. PubMed ID: 26630683
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circulating tumor DNA (ctDNA) detection is associated with shorter progression-free survival in advanced melanoma patients.
    Marczynski GT; Laus AC; Dos Reis MB; Reis RM; Vazquez VL
    Sci Rep; 2020 Oct; 10(1):18682. PubMed ID: 33122747
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lymph node metastases of melanoma: challenges for BRAF mutation detection.
    Chen G; Dudley J; Tseng LH; Smith K; Gurda GT; Gocke CD; Eshleman JR; Lin MT
    Hum Pathol; 2015 Jan; 46(1):113-9. PubMed ID: 25456393
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BRAF V600 Mutational Status in Melanoma Correlates with Cytologic Features in Fine-Needle Aspirate Specimens.
    Lee PJ; Dennis K; Madan R; Fan F
    Acta Cytol; 2019; 63(1):10-16. PubMed ID: 30396186
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection and Monitoring of the BRAF Mutation in Circulating Tumor Cells and Circulating Tumor DNA in BRAF-Mutated Lung Adenocarcinoma.
    Guibert N; Pradines A; Casanova A; Farella M; Keller L; Soria JC; Favre G; Mazières J
    J Thorac Oncol; 2016 Sep; 11(9):e109-12. PubMed ID: 27165943
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
    Yaman B; Akalin T; Kandiloğlu G
    Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficient treatment of a metastatic melanoma patient with a combination of BRAF and MEK inhibitors based on circulating tumor DNA analysis: a case report.
    Quéreux G; Herbreteau G; Knol AC; Vallée A; Khammari A; Théoleyre S; Saint-Jean M; Dréno B; Denis MG
    BMC Res Notes; 2017 Jul; 10(1):320. PubMed ID: 28743309
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Usefulness of immunocytochemistry for the detection of the BRAF(V600E) mutation in circulating tumor cells from metastatic melanoma patients.
    Hofman V; Ilie M; Long-Mira E; Giacchero D; Butori C; Dadone B; Selva E; Tanga V; Passeron T; Poissonnet G; Emile JF; Lacour JP; Bahadoran P; Hofman P
    J Invest Dermatol; 2013 May; 133(5):1378-81. PubMed ID: 23303445
    [No Abstract]   [Full Text] [Related]  

  • 33. Metastatic Malignant Melanoma With Complete Loss of Differentiation Markers (Undifferentiated/Dedifferentiated Melanoma): Analysis of 14 Patients Emphasizing Phenotypic Plasticity and the Value of Molecular Testing as Surrogate Diagnostic Marker.
    Agaimy A; Specht K; Stoehr R; Lorey T; Märkl B; Niedobitek G; Straub M; Hager T; Reis AC; Schilling B; Schneider-Stock R; Hartmann A; Mentzel T
    Am J Surg Pathol; 2016 Feb; 40(2):181-91. PubMed ID: 26448190
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRAF mutation testing in melanoma: results from a German observational multicenter study.
    Hartmann A; Schirmacher P; Sterlacci W; Koch W; Liesenfeld DB; Schif B; Garbe C
    Virchows Arch; 2019 Jan; 474(1):71-78. PubMed ID: 30406424
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Investigation of BRAF mutation analysis with different technical platforms in metastatic melanoma.
    Sener E; Yildirim P; Tan A; Gokoz O; Tezel GG
    Pathol Res Pract; 2017 May; 213(5):522-530. PubMed ID: 28216139
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Eradication of BRAF K601E Mutation in Metastatic Castrate-resistant Prostate Cancer Treated With Cabazitaxel and Carboplatin: A Case Report.
    Steinwald P; Ledet E; Sartor O
    Clin Genitourin Cancer; 2020 Jun; 18(3):e312-e314. PubMed ID: 31917173
    [No Abstract]   [Full Text] [Related]  

  • 37. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
    Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
    JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictive Significance of Combined Plasmatic Detection of BRAF Mutations and S100B Tumor Marker in Early-Stage Malignant Melanoma.
    Polivka J; Gouda MA; Sharif M; Pesta M; Huang H; Treskova I; Woznica V; Windrichova J; Houfkova K; Kucera R; Fikrle T; Ricar J; Pivovarcikova K; Topolcan O; Janku F
    Cancer Med; 2024 Oct; 13(19):e70313. PubMed ID: 39387479
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BRAF V600E mutation-specific antibody: A review.
    Ritterhouse LL; Barletta JA
    Semin Diagn Pathol; 2015 Sep; 32(5):400-8. PubMed ID: 25744437
    [TBL] [Abstract][Full Text] [Related]  

  • 40. USE OF CIRCULATING TUMOR DNA FOR DETECTION OF BRAF V600E MUTATION AND TREATMENT MONITORING IN MELANOMA PATIENTS.
    Shapochka D; Shapochka T; Seleznyov O; Matveeva A; Dudin V
    Georgian Med News; 2018 Mar; (276):76-81. PubMed ID: 29697386
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.